82 related articles for article (PubMed ID: 8510919)
1. Method of identifying inhibitors of oncogenic transformation: selective inhibition of cell growth in serum-free medium.
Li PM; Fukazawa H; Yamamoto C; Mizuno S; Tanaka K; Hori M; Yaginuma S; Saito T; Uehara Y
Oncogene; 1993 Jul; 8(7):1731-5. PubMed ID: 8510919
[TBL] [Abstract][Full Text] [Related]
2. [Protein kinase inhibitors--screening of new molecular target therapeutics].
Uehara Y
Gan To Kagaku Ryoho; 1997 Jan; 24(2):136-44. PubMed ID: 9030224
[TBL] [Abstract][Full Text] [Related]
3. Rit, a non-lipid-modified Ras-related protein, transforms NIH3T3 cells without activating the ERK, JNK, p38 MAPK or PI3K/Akt pathways.
Rusyn EV; Reynolds ER; Shao H; Grana TM; Chan TO; Andres DA; Cox AD
Oncogene; 2000 Sep; 19(41):4685-94. PubMed ID: 11032018
[TBL] [Abstract][Full Text] [Related]
4. Reversal of transformed phenotypes by herbimycin A in src oncogene expressed rat fibroblasts.
Murakami Y; Mizuno S; Hori M; Uehara Y
Cancer Res; 1988 Mar; 48(6):1587-90. PubMed ID: 3345529
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of pp60c-src protein kinase by herbimycin A in polyomavirus middle tumor antigen-transformed cells.
Yang YW; Chang YH
Anticancer Res; 1997; 17(5A):3273-9. PubMed ID: 9413159
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative.
Buchdunger E; Zimmermann J; Mett H; Meyer T; Müller M; Druker BJ; Lydon NB
Cancer Res; 1996 Jan; 56(1):100-4. PubMed ID: 8548747
[TBL] [Abstract][Full Text] [Related]
7. An anti-Ras cancer potential of PP1, an inhibitor specific for Src family kinases: in vitro and in vivo studies.
He H; Hirokawa Y; Levitzki A; Maruta H
Cancer J; 2000; 6(4):243-8. PubMed ID: 11038144
[TBL] [Abstract][Full Text] [Related]
8. Choline kinase inhibitors as a novel approach for antiproliferative drug design.
Hernández-Alcoceba R; Saniger L; Campos J; Núñez MC; Khaless F; Gallo MA; Espinosa A; Lacal JC
Oncogene; 1997 Nov; 15(19):2289-301. PubMed ID: 9393874
[TBL] [Abstract][Full Text] [Related]
9. Phorbol ester-induced production of cytostatic factors by normal and oncogenic Ha-ras-transformed human breast cell lines.
Guo M; Reiners JJ
Carcinogenesis; 2000 Jul; 21(7):1303-12. PubMed ID: 10874007
[TBL] [Abstract][Full Text] [Related]
10. Antiproliferative effects of heparin on normal and transformed NIH/3T3 fibroblasts.
Cavari S; Ruggiero M; Vannucchi S
Cell Biol Int; 1993 Aug; 17(8):781-6. PubMed ID: 8106075
[TBL] [Abstract][Full Text] [Related]
11. Raf and RhoA cooperate to transform intestinal epithelial cells and induce growth resistance to transforming growth factor beta.
Du J; Jiang B; Coffey RJ; Barnard J
Mol Cancer Res; 2004 Apr; 2(4):233-41. PubMed ID: 15140945
[TBL] [Abstract][Full Text] [Related]
12. Thrombospondin-1 suppresses tumorigenesis and angiogenesis in serum- and anchorage-independent NIH 3T3 cells.
Castle VP; Dixit VM; Polverini PJ
Lab Invest; 1997 Jul; 77(1):51-61. PubMed ID: 9251678
[TBL] [Abstract][Full Text] [Related]
13. Multiple aspects of the phenotype of mammary epithelial cells transformed by expression of activated M-Ras depend on an autocrine mechanism mediated by hepatocyte growth factor/scatter factor.
Zhang KX; Ward KR; Schrader JW
Mol Cancer Res; 2004 Apr; 2(4):242-55. PubMed ID: 15140946
[TBL] [Abstract][Full Text] [Related]
14. Reexpression of the major protein kinase C substrate, SSeCKS, suppresses v-src-induced morphological transformation and tumorigenesis.
Lin X; Gelman IH
Cancer Res; 1997 Jun; 57(11):2304-12. PubMed ID: 9187136
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor regulates protein kinase A activity in murine fibrosarcoma cells: differences between metastatic and nonmetastatic tumor cell variants.
Fishman D; Galitzki L; Priel E; Segal S
Cancer Res; 1997 Dec; 57(23):5410-5. PubMed ID: 9393768
[TBL] [Abstract][Full Text] [Related]
16. Effects of a conditionally active v-ErbB and an EGF-R inhibitor on transformation of NIH-3T3 cells and abrogation of cytokine dependency of hematopoietic cells.
McCubrey JA; Shelton JG; Steelman LS; Franklin RA; Sreevalsan T; McMahon M
Oncogene; 2004 Oct; 23(47):7810-20. PubMed ID: 15361836
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of oncogene-mediated transformation by ectopic expression of p21Waf1 in NIH3T3 cells.
Michieli P; Li W; Lorenzi MV; Miki T; Zakut R; Givol D; Pierce JH
Oncogene; 1996 Feb; 12(4):775-84. PubMed ID: 8632899
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of cell growth: effects of the tyrosine kinase inhibitor CGP 53716.
Major TC; Keiser JA
J Pharmacol Exp Ther; 1997 Oct; 283(1):402-10. PubMed ID: 9336349
[TBL] [Abstract][Full Text] [Related]
19. Oncogenic transformation potentiates apoptosis, S-phase arrest and stress-kinase activation by etoposide.
Chen G; Shu J; Stacey DW
Oncogene; 1997 Oct; 15(14):1643-51. PubMed ID: 9349497
[TBL] [Abstract][Full Text] [Related]
20. Ornithine decarboxylase induction in transformation by H-Ras and RhoA.
Shantz LM; Pegg AE
Cancer Res; 1998 Jul; 58(13):2748-53. PubMed ID: 9661886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
